Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.77 |
| ▸ | SHBG | P04278 | 6/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.77 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.77 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.77 |
| ▸ | SNCA | P37840 | 4/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.77 |
| ▸ | TSHR | P16473 | 4/20 | 0.77 |
| ▸ | BLM | P54132 | 3/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.77 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.77 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.66 |
| ▸ | PGR | P06401 | 5/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | AR | P10275 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22476664 | 1.00 | CYP19A1 (0.77) | CYP19A1SHBGHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL14422722 | 1.00 | CYP19A1 (0.77) | CYP19A1SHBGHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL5151424 | 1.00 | CYP19A1 (0.77) | CYP19A1SHBGHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL22704745 | 1.00 | CYP19A1 (0.77) | CYP19A1SHBGHSD17B10SMN1; SMN2LMNA | |
| Androstenedione SCHEMBL13752932 | 0.87 | CYP19A1 (1.00) | CYP19A1SHBGHSD17B10SMN1; SMN2LMNA | |
| Androstenedione SCHEMBL13753017 | 0.87 | CYP19A1 (1.00) | CYP19A1SHBGHSD17B10SMN1; SMN2LMNA | |
| Androstenedione SCHEMBL9310209 | 0.87 | CYP19A1 (1.00) | CYP19A1SHBGHSD17B10SMN1; SMN2LMNA | |
| Androstenedione SCHEMBL11876371 | 0.87 | CYP19A1 (1.00) | CYP19A1SHBGHSD17B10SMN1; SMN2LMNA | |
| Androstenedione SCHEMBL21265627 | 0.87 | CYP19A1 (1.00) | CYP19A1SHBGHSD17B10SMN1; SMN2LMNA | |
| Androstenedione SCHEMBL15369366 | 0.87 | CYP19A1 (1.00) | CYP19A1SHBGHSD17B10SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392320-B1 | 17-METHYLENE-ANDROSTAN-3a-OL ANALOGS AS CRH INHIBITORS | PHERIN PHARM INC (US) | 2007-01-10 | — | — | EP | claimed |
| EP-1549292-A2 | PHARMACEUTICAL PREPARATIONS, USE OF SAID PREPARATIONS AND METHOD FOR INCREASING THE BIOAVAILABILITY OF MEDICAMENTS FOR PERORAL ADMINISTRATION | Schering Aktiengesellschaft (DE) | 2005-07-06 | — | — | EP | claimed |
| WO-2004032897-A2 | PHARMACEUTICAL PREPARATIONS, USE OF SAID PREPARATIONS AND METHOD FOR INCREASING THE BIOAVAILABILITY OF MEDICAMENTS FOR PERORAL ADMINISTRATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-22 | — | — | WO | claimed |
| EP-1392320-A1 | 17-METHYLENE-ANDROSTAN-3a-OL ANALOGS AS CRH INHIBITORS | Pherin Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030220309-A1 | 17-methylenandrostan-3alpha-ol analogs as CRH inhibitors | PHERIN PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | claimed |
| US-20030045514-A1 | 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors | JULIAN N. STERN, A PROFESSIONAL CORPORATION | 2003-03-06 | — | — | US | claimed |
| WO-2002089814-A1 | 17-METHYLENE-ANDROSTAN-3α-OL ANALOGS AS CRH INHIBITORS | PHERIN PHARMACEUTICALS, INC. (US) | 2002-11-14 | — | — | WO | claimed |
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
| WO-2010066349-A1 | USE OF 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-17 | — | — | WO | disclosed |
| EP-2167525-A2 | 17ß-CYANO-19-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008152112-A2 | 17ß-CYANO-19-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
| EP-1392320-B1 | 17-METHYLENE-ANDROSTAN-3a-OL ANALOGS AS CRH INHIBITORS | PHERIN PHARM INC (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-0891188-A4 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | PHERIN PHARM INC (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-1998014194-A1 | STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF ANXIETY | PHERIN PHARMACEUTICALS (US) | 1998-04-09 | — | — | WO | disclosed |
| WO-1998003207-A1 | STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF PMS AND ANXIETY | PHERIN PHARMACEUTICALS, INC. (US) | 1998-01-29 | — | — | WO | disclosed |
| WO-1997036596-A9 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | — | 1997-12-04 | — | — | WO | disclosed |
| WO-1997036596-A1 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | PHERIN PHARMACEUTICALS, INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0783512-A1 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORPORATION (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010031-A1 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORPORATION (US) | 1996-04-04 | — | — | WO | disclosed |
| EP-0122232-A1 | 20-Spiroxanes and analogues with open ring E, process for their preparation and pharmaceutical compositions | CIBA-GEIGY AG (CH) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220309-A1 | 17-methylenandrostan-3alpha-ol analogs as CRH inhibitors | CRH, CRHR1, CRHR2 | CYP19A1 691/4885SHBG 170/4885HSD17B10 216/4885 |
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | CYP19A1 14/4885SHBG 24/4885HSD17B10 54/4885 |
| US-20030045514-A1 | 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors | CRH, CRHR1, CRHR2 | CYP19A1 256/4885SHBG 88/4885HSD17B10 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.